Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV
- PMID: 40854701
- PMCID: PMC12616793
- DOI: 10.3122/jabfm.2025.250014R0
Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV
Abstract
Initiation of pitavastatin in adults aged 40 to 75 living with HIV treated with highly active antiretroviral therapy (HAART) with low-to-moderate 10-year atherosclerotic cardiovascular disease (ASCVD) risk decreases the incidence of major cardiovascular events (MACE).
Keywords: HIV; Hyperlipidemia; Statin.
© 2025 Copyright by the American Board of Family Medicine.
Conflict of interest statement
Funding: None. The authors declare no conflict of interest.
References
-
- Grand M, Bia D, Diaz A. Cardiovascular risk assessment in people living with HIV: a systematic review and meta-analysis of real-life data. Curr HIV Res 2020;18:5–18. - PubMed
-
- Friis-Møller N, Reiss P, Sabin CA, DAD Study Group et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723–35. - PubMed
-
- Friis-Møller N, Sabin CA, Weber R, Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993–2003.
-
- Spector A. HIV protease inhibitors and hyperlipidemia. Arterioscler Thromb Vasc Biol 2006;26:7–9. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical